Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 7/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582322 | 0.93 | BRAF (0.62) | BRAFRETKDRLMNAGAA | |
| SCHEMBL2579573 | 0.92 | BRAF (0.55) | BRAFRETKDRLMNAGAA | |
| SCHEMBL2577906 | 0.90 | KDR (0.62) | BRAFRETKDRRAF1CCNC | |
| SCHEMBL2576492 | 0.89 | RAF1 (0.54) | BRAFKDRLMNAGAAMAPT | |
| SCHEMBL2590020 | 0.87 | BRAF (0.58) | BRAFRETKDRLMNAGAA | |
| SCHEMBL16477699 | 0.85 | BRAF (0.47) | BRAFKDRMAPTRAF1 | |
| SCHEMBL2584007 | 0.84 | BRAF (0.62) | BRAFRETKDRLMNAGAA | |
| SCHEMBL2577878 | 0.84 | KDR (0.70) | BRAFRETKDRRAF1CCNC | |
| SCHEMBL2586109 | 0.82 | RAF1 (0.55) | BRAFKDRLMNAGAAMAPT | |
| SCHEMBL2579416 | 0.80 | BRAF (0.65) | BRAFRETKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049014-B2 | Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-11-01 | — | — | US | claimed |
| US-20100249182-A1 | AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KP) | 2010-09-30 | — | — | US | claimed |
| US-8049014-B2 | Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20100249182-A1 | AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249182-A1 | AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | NRAS, SFPQ, TYR | BRAF 29/4885RET 1430/4885KDR 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.